Decision is delayed on whether Avastin can stay a breast cancer drug

09/19/2010 | Reuters

The FDA extended until Dec. 17 a review of Genentech's two applications for Avastin as a combination treatment with other types of chemotherapy for breast cancer. The move comes after the company submitted additional information on the drug's wider uses. The agency has not decided whether to remove Avastin's marketing approval for breast cancer, as recommended by advisers.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA